Richard van Zyl-Smit (University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa) kindly took the time to speak with us about maximising the benefit of inhaler therapy and recent development being made in this field.
Questions
- What are the major unmet needs in the use of inhaled therapies for the control of asthma? (0:15)
- How can we help patients optimise their inhaler technique? (0:55)
- How can we maximise the benefits of inhaler therapy over 24 hours? (1:46)
- Which asthma patients are most likely to benefit from once daily single inhaler triple therapy? (2:39)
- What have been the most exciting recent developments in inhaler therapy? (3:49)
Speaker disclosure: Richard van Zyl-Smith has conducted clinical research trials for Novartis, AstraZeneca, Takeda, Merck, Almirall, Boehringer Ingelheim, Sanofi, Teva, Perl, Pfizer, Roche, GSK and Genetech. He has also received honoraria for academic talks from, Aspen, Pfizer, AstraZeneca, Novartis, Cipla, MSD, Roche, Jannsen, Boehringer Ingelheim and participated in advisory boards for GSK, Pfizer, AstraZeneca, Novartis, MSD and Roche.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ERS International Congress 2020
